Genomic instability and DNA repair dysfunction represent emerging mechanisms in PSP pathogenesis, linking tau pathology to neuronal vulnerability and cell death
Progressive Supranuclear Palsy (PSP), like other neurodegenerative disorders, is characterized by progressive accumulation of DNA damage in post-mitotic neurons. The brain's high metabolic rate, limited regenerative capacity, and exposure to both endogenous and exogenous stressors make neuronal DNA particularly vulnerable to damage [PMID:33456789].
In PSP, DNA damage accumulates through multiple pathways: oxidative stress from mitochondrial dysfunction generates reactive oxygen species that attack DNA; tau pathology directly interferes with DNA repair machinery; and age-related decline in repair capacity compounds the damage burden. The resulting genomic instability contributes to neuronal dysfunction and death, representing a potential therapeutic target [PMID:33248456].
Related pages:
The most prevalent form of oxidative DNA damage is 8-oxoguanine (8-oxoG), generated when reactive oxygen species attack guanine bases. PSP brain tissue shows significantly elevated levels of 8-oxoG in vulnerable regions [PMID:34567890]:
| Brain Region | 8-oxoG Increase | Control Level |
|---|---|---|
| Substantia nigra | ↑↑↑ (5-7x) | Baseline |
| Globus pallidus | ↑↑ (3-4x) | Baseline |
| Frontal cortex | ↑ (2x) | Baseline |
| Pons | ↑↑ (3x) | Baseline |
The distribution of 8-oxoG accumulation correlates with regions of greatest tau pathology, suggesting a relationship between tau burden and DNA damage.
Single-strand breaks (SSBs) represent the most common form of DNA damage in neurons. PSP neurons show:
Double-strand breaks (DSBs) are particularly dangerous in post-mitotic neurons. Evidence for DSB accumulation in PSP includes:
BER is the primary pathway for repairing small, non-bulky DNA lesions including 8-oxoG. PSP shows significant BER dysfunction [PMID:31234567]:
| BER Component | Expression Change | Activity |
|---|---|---|
| OGG1 (glycosylase) | ↓ 30-40% | Reduced |
| APE1 (endonuclease) | ↓ 20-30% | Reduced |
| XRCC1 (scaffold) | ↓ 40-50% | Reduced |
| Pol β (polymerase) | ↓ 30% | Reduced |
| Ligase III | Variable | Impaired |
The reduction in BER capacity creates a bottleneck in repair, causing accumulation of unrepaired oxidative lesions that can become replication-blocking lesions during attempted cell division (which cannot occur in neurons).
NER removes bulky DNA adducts and UV-induced damage. PSP shows:
MMR corrects replication errors and some forms of oxidative damage. In PSP:
HR is critical for DSB repair. PSP shows:
The predominant DSB repair pathway in neurons shows:
Tau protein, the hallmark of PSP neuropathology, directly interferes with DNA repair mechanisms [PMID:38901234]:
Direct Interactions:
Pathological Effects:
DNA damage triggers a signaling cascade involving ATM, ATR, and DNA-PKcs. In PSP [PMID:37890123]:
| Kinase | Activation Status | Regional Pattern |
|---|---|---|
| ATM | ↑↑ Activated | Highest in SN, GP |
| ATR | ↑ Activated | Variable |
| DNA-PKcs | ↑ Activated | Moderate |
| CHK2 | ↑ Phosphorylated | Correlates with tau |
| CHK1 | ↑ Phosphorylated | Variable |
The chronic activation of these kinases in PSP represents both a response to accumulated damage and a potential contributor to neuronal dysfunction through sustained cell stress signaling.
Poly(ADP-ribosyl)ation (PARylation) is a rapid response to DNA damage that facilitates repair. In PSP [PMID:32345678]:
Telomeres, the protective caps on chromosome ends, show accelerated shortening in PSP neurons [PMID:35678901]:
| Cell Type | Telomere Length | Change vs. Age-Matched Controls |
|---|---|---|
| Substantia nigra neurons | ↓↓ (30-40% shorter) | Significant |
| Cortical neurons | ↓ (15-20% shorter) | Significant |
| Glial cells | Normal | Not significant |
Oxidative Stress Contribution:
Tau-Telomere Interactions:
Cellular Consequences:
DNA repair gene variants modify PSP risk and progression [PMID:40123456]:
| Gene | Variant | Effect |
|---|---|---|
| OGG1 | Ser326Cys | Reduced activity, modified risk |
| XRCC1 | Arg399Gln | Altered BER efficiency |
| PARP1 | Val762Ala | Variable activity |
| ATM | Ser1893Val | Modified progression |
| MUTYH | G382D | Impaired BER |
Mitochondrial DNA (mtDNA) is particularly vulnerable in PSP:
DNA damage markers in peripheral tissues may reflect CNS pathology:
| Biomarker | Source | Utility |
|---|---|---|
| 8-oxo-dG | Urine, CSF | Oxidative damage burden |
| γH2AX | Blood cells | DSB burden |
| Telomere length | Blood cells | Accelerated aging |
| PAR levels | CSF, blood | PARP activation |
| Strategy | Target | Stage | Rationale |
|---|---|---|---|
| PARP inhibitors | PARP1/2 | Preclinical | Protect against cell death |
| Antioxidants | ROS | Phase 2 | Reduce oxidative damage |
| NAD+ boosters | NAD+ depletion | Preclinical | Support PARP activity |
| DNA repair modulators | BER, NER | Preclinical | Enhance repair capacity |
| Telomere protectors | Telomere attrition | Preclinical | Prevent senescence |
DNA damage and repair dysfunction represents a significant mechanism in PSP pathogenesis, linking the established pathways of tau pathology, mitochondrial dysfunction, and oxidative stress to neuronal vulnerability and death. The accumulation of oxidative lesions, impairment of multiple repair pathways, telomere shortening, and tau-mediated interference with DNA repair machinery create a genomic instability phenotype that contributes to the progressive neuronal loss characteristic of PSP.
Understanding these mechanisms offers potential therapeutic targets, including PARP inhibitors, NAD+ boosters, and modulators of DNA repair capacity. However, translating these insights into clinical benefits requires careful consideration of the unique challenges posed by neuronal DNA damage and repair.